Interestingly, adoptive immunotherapy with in vitro-expanded autologous EBV-specific CD8+ T-cells in secondary progressive MS had no adverse effects and was associated with clinical improvement and reduced disease activity on MRI (146). The gene discussed is CD8A; the disease is myeloid sarcoma.